210 related articles for article (PubMed ID: 30235516)
1. The Regulation of Companion Diagnostics: A Global Perspective.
Ansari M
Ther Innov Regul Sci; 2013 Jul; 47(4):405-415. PubMed ID: 30235516
[TBL] [Abstract][Full Text] [Related]
2. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
3. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
Front Genet; 2015; 6():357. PubMed ID: 26858745
[TBL] [Abstract][Full Text] [Related]
4. The current and future state of companion diagnostics.
Agarwal A; Ressler D; Snyder G
Pharmgenomics Pers Med; 2015; 8():99-110. PubMed ID: 25897259
[TBL] [Abstract][Full Text] [Related]
5. Challenges in the codevelopment of companion diagnostics.
Moore MW; Babu D; Cotter PD
Per Med; 2012 Jul; 9(5):485-496. PubMed ID: 29768776
[TBL] [Abstract][Full Text] [Related]
6. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
Cowling T; Boucher M
Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
[TBL] [Abstract][Full Text] [Related]
7. Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects.
Olsen D; Jørgensen JT
Front Oncol; 2014; 4():105. PubMed ID: 24904822
[TBL] [Abstract][Full Text] [Related]
8. The current landscape of the FDA approved companion diagnostics.
Jørgensen JT
Transl Oncol; 2021 Jun; 14(6):101063. PubMed ID: 33714919
[TBL] [Abstract][Full Text] [Related]
9. Companion and complementary diagnostics for infectious diseases.
Dailey PJ; Elbeik T; Holodniy M
Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
[TBL] [Abstract][Full Text] [Related]
10. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
Roscoe DM; Hu YF; Philip R
Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
[TBL] [Abstract][Full Text] [Related]
11. Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics.
Halim AB
Ann N Y Acad Sci; 2015 Jun; 1346(1):63-70. PubMed ID: 25758153
[TBL] [Abstract][Full Text] [Related]
12. Biopharmaceutical industry perspectives on the business prospects for personalized medicine.
Milne CP; Zuckerman R
Per Med; 2011 Sep; 8(5):541-550. PubMed ID: 29793252
[TBL] [Abstract][Full Text] [Related]
13. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
[TBL] [Abstract][Full Text] [Related]
14. Twenty-five years with companion diagnostics.
Jørgensen JT
Chin Clin Oncol; 2023 Dec; 12(6):65. PubMed ID: 37953243
[TBL] [Abstract][Full Text] [Related]
15. Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS.
Kang SL; Woo JH; Kim NH; Kwon JY; Kim SM
Mol Ther Methods Clin Dev; 2023 Sep; 30():447-458. PubMed ID: 37663648
[TBL] [Abstract][Full Text] [Related]
16. Companion Diagnostics and Molecular Imaging.
Puranik AD; Kulkarni HR; Baum RP
Cancer J; 2015; 21(3):213-7. PubMed ID: 26049701
[TBL] [Abstract][Full Text] [Related]
17. Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan.
Tanaka A; Suzuki H; Toyoshima S; Nagai N
Ther Innov Regul Sci; 2022 Jan; 56(1):85-95. PubMed ID: 34406635
[TBL] [Abstract][Full Text] [Related]
18. Regulatory considerations for companion diagnostic devices.
Lee EY; Shen HC
Biomark Med; 2015; 9(1):67-75. PubMed ID: 25605456
[TBL] [Abstract][Full Text] [Related]
19. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
Love D; Stratton E; Stocum M
N Biotechnol; 2012 Sep; 29(6):689-94. PubMed ID: 22743138
[TBL] [Abstract][Full Text] [Related]
20. Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries.
Govaerts L; Simoens S; Van Dyck W; Huys I
Value Health; 2020 May; 23(5):606-615. PubMed ID: 32389226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]